ECG
RETA

Edge Capital Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Edge Capital Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-25,788
Closed -$2.2M – 262
2019
Q1 		$2.2M Buy
+25,788
New +$2.14M 0.22% 85

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Edge Capital Group's RETA Position: Q2 2019 in Review

Edge Capital Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2019, closing a stake of 25,788 shares — an estimated $2.2M sold.

Edge Capital Group first reported a position in RETA in Q1 2019 and held it in 1 quarter. The position peaked at $2.2M in Q1 2019. 158 funds tracked by Wall St. Rank hold RETA as of Q2 2019.

  • Edge Capital Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2019 after selling out during the quarter.
  • Edge Capital Group sold 25,788 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2019, an estimated $2.2M.
  • Edge Capital Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 1 quarter.
  • Edge Capital Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.2M in Q1 2019.
  • 158 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2019.

Based on Edge Capital Group's 13F filing for Q2 2019, filed 25 Jul 2019.